Abstract:Introduction: Young healthy donor mesenchymal stem cells (MSCs) are very good candidates for heart repair as they are immunoprivileged and have excellent regenerative capacity. We showed that allogeneic MSCs reduced host immune response and survived early after injection into the ischemic myocardium, but later lost their immunoprivilege and were rejected. Here we show the mechanisms responsible for this immune switch and suggest a way to preserve immunoprivilege and heart function. Methods/Results: Allogeneic MSCs were co-cultured with lymphocytes and allo-immune responses were assessed. MSC immunoprivilege was mediated by the immunosuppressive cytokine interleukin-10 (IL-10), as the level of lymphocyte-mediated cytotoxicity was significantly greater for IL-10 knock-out MSCs compared to wild-type. Myogenic differentiation of MSCs led to decreased IL-10 levels and loss of immunoprivilege. Adenovirus-mediated IL-10 gene transfer to differentiated MSCs (DMSCs) decreased cytotoxicity and preserved immunoprivilege. In a rat MI model, allogeneic MSCs transplanted into the infarct region were mostly rejected by 5 weeks. Maintaining IL-10 levels in MSCs prevented anti-donor antibodies against transplanted MSCs and increased cell survival. IL-10 over-expressing MSCs also improved %FS and LV dimensions compared to media injected controls. IL-10 gene therapy in allogeneic MSCs also prevented scar thinning. To investigate further, we co-cultured allogeneic MSCs with lymphocytes for 72h and found that undifferentiated MSCs promoted immune suppression by decreasing lymphocyte proliferation and increasing production of regulatory T cells (Tregs), whereas DMSCs did not inhibit lymphocyte proliferation or induce Treg production. IL-10 over-expression in DMSCs preserved immunoprivilege by decreasing lymphocyte proliferation and by increasing Treg production. Conclusion: IL-10 mitigated the recipient’s allo-immune responses against transplanted MSCs. MSC differentiation led to decreased IL-10, reduced ability to suppress cytotoxic lymphocytes, and loss of immune privilege. Maintaining IL-10 levels preserved immune privilege, increased survival of transplanted MSCs and restored cardiac function after MI.

Inhibiting Immune Rejection And Enhancing Ischemic Hindlimb Repair By B2m Knockdown In Allogeneic Human Msc Using Crispr/Cas9 Technology

Downregulation Of B2m In Allogeneic Msc By Crispr Technology Inhibits Immune Rejection And Enhances Cardiac Repair

Enhancing Cardiac Repair by Allogeneic MSC via Downregulation of B2M by CRISPR/Cas9 Technology

Knockout of Beta-2 Microglobulin Reduces Stem Cell-Induced Immune Rejection and Enhances Ischemic Hindlimb Repair Via Exosome/mir-24/Bim Pathway in Mice

Knockout of beta-2 microglobulin enhances cardiac repair by modulating exosome imprinting and inhibiting stem cell-induced immune rejection

Knockout of beta‐2 microglobulin reduces stem cell‐induced immune rejection and enhances ischaemic hindlimb repair via exosome/miR‐24/Bim pathway

Therapeutic Angiogenesis of Bone Marrow Mononuclear Cells (mncs) and Peripheral Blood Mncs: Transplantation for Ischemic Hindlimb

CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy

Rap1 Deficiency-Provoked Paracrine Dysfunction Impairs Immunosuppressive Potency of Mesenchymal Stem Cells in Allograft Rejection of Heart Transplantation

MHC Class I Enables MSCs to Evade NK-Cell-Mediated Cytotoxicity and Exert Immunosuppressive Activity

Downregulating human leucocyte antigens on mesenchymal stromal cells by epigenetically repressing a β2-microglobulin super-enhancer

Downregulating human leucocyte antigens on mesenchymal stromal cells by epigenetically repressing a β 2 -microglobulin super-enhancer

Unveiling the immunogenicity of allogeneic mesenchymal stromal cells: Challenges and strategies for enhanced therapeutic efficacy

Abstract 15547: Restoration of Interleukin-10 Levels in Differentiated Mesenchymal Stem Cells Preserves Their Immunoprivilege in Allogeneic Implantation and Restores Post-Infarction Cardiac Function

Human amniotic mesenchymal stem cells inhibit immune rejection injury from allogeneic mouse heart transplantation: A preliminary study on the microRNA expression

Insensitivity of Human iPS Cells-Derived Mesenchymal Stem Cells to Interferon-γ-induced HLA Expression Potentiates Repair Efficiency of Hind Limb Ischemia in Immune Humanized NOD Scid Gamma Mice

Dose- And Time-Dependent Effects Of Human Mesenchymal Stromal Cell Infusion On Cardiac Allograft Rejection In Mice

Stromal Cells Act as Guardians for Endothelial Progenitors by Reducing Their Immunogenicity After Co-Transplantation

CD4+ CTLs Act as a Key Effector Population for Allograft Rejection of MSCs in a Donor MHC-II Dependent Manner in Injured Liver

Syngeneic Mesenchymal Stem Cells Reduce Immune Rejection After Induced Pluripotent Stem Cell-Derived Allogeneic Cardiomyocyte Transplantation

Overexpression of Hsp 70 enhances MSCs survival and therapeutic efficiency in hindlimb ischemia